Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mario Boehm (Giessen, Germany), Mario Boehm, Baktybek Kojonazarov, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Norbert Weissmann, John T. Liles, Grant R. Budas, Werner Seeger, Ralph T. Schermuly. Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction. Eur Respir J 2015; 46: Suppl. 59, 4913

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of p38 MAPK improves heart function in experimental pressure-overload induced right ventricular hypertrophy and failure Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Selective TSC1 deletion in smooth muscle activates mTOR signaling and induces pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Right heart hypertrophy in mice deficient of the mitochondrial regulator protein p66shc is decreased after chronic hypoxic exposure by a cyclophilin D dependent mechanism Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008 Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Siah2 in pulmonary hypertension and right ventricular hypertrophy Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The hsp90 inhibitor, 17-AAG prevents and reverses the increases in lung calcineurin expression and activity associated with monocrotaline-induced right ventricular hypertrophy Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 The effect of ASK1 inhibition on hypoxia-induced pulmonary artery fibroblast activation and associated paracrine effects on vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016